A JAMA case report has reported that regions showing extensive amyloid removal after amyloid-targeting therapies in Alzheimer’s disease also show reductions in subsequent neuropathologic changes. The study frames amyloid burden as closely tied to downstream disease progression by correlating removal with later pathologic findings. Researchers observed that where amyloid clearance was most pronounced, the follow-on neuropathologic alterations were less extensive, supporting a mechanistic link between plaque reduction and disease biology. Amyloid clearance refers to the reduction of amyloid plaques (the hallmark protein aggregates) after treatment. While case reports are not definitive for causal inference, the findings add clinical-pathologic evidence to the ongoing debate over how effectively plaque-targeting therapies translate into slower neurodegeneration. The work arrives as Alzheimer’s research remains focused on biomarkers, target engagement, and real-world neuropathologic outcomes.